SELLAS Life Sciences Group, Inc. financial data

Symbol
SLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
7 Times Square, Suite 2503, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
GALENA BIOPHARMA, INC. (to 12/15/2017), Galena Biopharma, Inc. (to 12/15/2017), RXI PHARMACEUTICALS CORP (to 9/21/2011)
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 159 % +73.2%
Debt-to-equity 125 % -86.1%
Return On Assets -144 % +40%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.8M shares +61.5%
Common Stock, Shares, Outstanding 74M shares +130%
Entity Public Float 68.6M USD +54.4%
Common Stock, Value, Issued 7K USD +133%
Weighted Average Number of Shares Outstanding, Basic 61.2M shares +120%
Weighted Average Number of Shares Outstanding, Diluted 61.2M shares +120%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Costs and Expenses 31.5M USD -16.8%
Operating Income (Loss) -31.5M USD +16.8%
Nonoperating Income (Expense) 632K USD +19.5%
Net Income (Loss) Attributable to Parent -30.9M USD +17.3%
Earnings Per Share, Basic -0.5 USD/shares +62.7%
Earnings Per Share, Diluted -0.5 USD/shares +62.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.9M USD +449%
Assets, Current 16.3M USD +415%
Operating Lease, Right-of-Use Asset 925K USD +7.81%
Goodwill 1.91M USD 0%
Assets 19.4M USD +212%
Accounts Payable, Current 3.5M USD -37.9%
Employee-related Liabilities, Current 1.78M USD +19%
Accrued Liabilities, Current 5.47M USD -28.5%
Liabilities, Current 9.51M USD -30.8%
Operating Lease, Liability, Noncurrent 457K USD -0.65%
Liabilities 9.97M USD -29.8%
Retained Earnings (Accumulated Deficit) -248M USD -14.2%
Stockholders' Equity Attributable to Parent 9.47M USD
Liabilities and Equity 19.4M USD +212%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8M USD +11.3%
Net Cash Provided by (Used in) Financing Activities 26.6M USD +41%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 74M shares +130%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 15.9M USD +134%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14M USD +432%
Deferred Tax Assets, Valuation Allowance 20.9M USD +11%
Deferred Tax Assets, Gross 21.1M USD +10.9%
Operating Lease, Liability 1M USD +10.5%
Lessee, Operating Lease, Liability, to be Paid 1.11M USD +10.1%
Operating Lease, Liability, Current 544K USD +22%
Lessee, Operating Lease, Liability, to be Paid, Year Two 477K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 635K USD +19.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 111K USD +6.73%
Deferred Tax Assets, Operating Loss Carryforwards 14.1M USD +15.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 500K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 200K USD +8.7%
Share-based Payment Arrangement, Expense 1.56M USD -25.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%